SCHEMBL22807414

SCHEMBL22807414

O=C(OC(=O)C(F)(F)F)c1[nH]nnc1C(F)(F)c1ccc(-c2ccc(Cl)c(Cl)c2)cc1

nearest known ligand 0.35

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CHUK O15111 1/20 0.35
▸ PTPN5 P54829 2/20 0.33
▸ SLC6A3 Q01959 1/20 0.32
▸ SCN9A Q15858 1/20 0.32
▸ KMO O15229 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ RCE1 Q9Y256 1/20 0.31
▸ NOTUM Q6P988 1/20 0.31
▸ HDAC6 Q9UBN7 1/20 0.30
▸ ARF6 P62330 1/20 0.30
▸ XDH P47989 2/20 0.30
▸ KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22608672 0.89 MAPT (0.33) —
SCHEMBL29514795 0.84 KMO (0.41) CHUKPTPN5SCN9AKMOXDH
SCHEMBL28464307 0.84 KMO (0.41) CHUKPTPN5SCN9AKMOXDH
Trifluoroacetic Acid SCHEMBL22807413 0.84 KMO (0.39) CHUKPTPN5SCN9AKMOXDH
SCHEMBL22608677 0.84 AURKA (0.38) NOTUMKMT2A
SCHEMBL22608229 0.82 MARS1 (0.36) —
SCHEMBL22807511 0.81 HAO1 (0.43) CHUK
SCHEMBL22608720 0.78 CHUK (0.36) CHUKSLC6A3KMO
SCHEMBL22608810 0.78 CHUK (0.33) CHUKSLC6A3XDHKMT2A
SCHEMBL22608476 0.74 HAO1 (0.37) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-23 — — US disclosed
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2023-03-16 — — US disclosed
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease BIOMARIN PHARMACEUTICAL INC. (US) 2022-07-12 — — US disclosed
EP-3986863-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BioMarin Pharmaceutical Inc. (US) 2022-04-27 — — EP disclosed
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2021-06-10 — — US disclosed
WO-2020257487-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2020-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079913-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CHUK 1339/4885PTPN5 1661/4885SLC6A3 1268/4885
US-20230088214-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CHUK 1513/4885PTPN5 1691/4885SLC6A3 1307/4885
US-11384055-B2 Glycolate oxidase inhibitors for the treatment of disease XDH, PNPO, AGXT CHUK 1339/4885PTPN5 1661/4885SLC6A3 1268/4885
US-20230089374-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CHUK 1339/4885PTPN5 1661/4885SLC6A3 1268/4885
US-20210171474-A1 GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE XDH, PNPO, AGXT CHUK 1339/4885PTPN5 1661/4885SLC6A3 1268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback